Traders With Significant Losses Have Chance to Guide the Athira Pharma, Inc. Class Action Lawsuit

SAN DIEGO, July 20, 2021–(Enterprise WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) securities amongst September 18, 2020 and June 17, 2021, inclusive (the “Class Time period”) have right until August 24, 2021 to look for appointment as guide plaintiff in the Athira Pharma course action lawsuit. The Athira Pharma class action lawsuit fees Athira Pharma and its CEO with violations of the Securities Trade Act of 1934. The Athira Pharma course action lawsuit (Wang v. Athira Pharma, Inc., No. 21-cv-00861) was commenced on June 25, 2021 in the Western District of Washington and is assigned to Decide Thomas S. Zilly. Two very similar lawsuits – Jawandha v. Athira Pharma, Inc., No. 21-cv-00862, and Slyne v. Athira Pharma, Inc., No. 21-cv-00864 – are also pending in the Western District of Washington.

If you endured sizeable losses and want to provide as direct plaintiff of the Athira Pharma course action lawsuit, you should supply your info by clicking in this article. You can also speak to lawyer J.C. Sanchez of Robbins Geller by contacting 800/449-4900 or by using e-mail at [email protected] Lead plaintiff motions for the Athira Pharma class motion lawsuit will have to be filed with the court docket no afterwards than August 24, 2021.

Circumstance ALLEGATIONS: The Athira Pharma course motion lawsuit alleges that, throughout the Course Time period, defendants manufactured wrong and misleading statements and unsuccessful to disclose that: (i) the analysis performed by Athira Pharma’s President and Main Government Officer, defendant Leen Kawas, which fashioned the basis for Athira Pharma’s product or service candidates and intellectual residence, was tainted by Kawas’s scientific misconduct, which include the manipulation of critical details and (ii) as a final result, defendants’ beneficial statements about Athira Pharma’s business, operations, and potential customers have been materially deceptive and omitted product facts needed to make the statements produced not deceptive.

On June 17, 2021, Athira Pharma issued a press launch announcing that Athira Pharma’s Board of Directors experienced positioned Kawas on non permanent go away pending a evaluate of steps stemming from doctoral exploration Kawas carried out even though at Washington Condition College. An post published in STAT News afterwards that day unveiled that the investigation of Kawas similar to allegations that she altered photos in 4 separate papers relating to her exploration on hepatocyte growth factor (HGF), a protein with the opportunity to handle Alzheimer’s disease and other neurological conditions. The post famous that while Athira Pharma “has since moved on to a different molecule than the a single Kawas was doing work on, it still aims to target HGF. And so Kawas’s doctoral operate laid the biological groundwork that Athira carries on to use in their method to treating Alzheimer’s.” On this information, Athira Pharma’s stock price fell by nearly 39%, detrimental traders.

THE Guide PLAINTIFF Procedure: The Private Securities Litigation Reform Act of 1995 permits any trader who ordered Athira Pharma securities for the duration of the Course Interval to search for appointment as guide plaintiff in the Athira Pharma class motion lawsuit. A guide plaintiff is frequently the movant with the best economical curiosity in the aid sought by the putative course who is also normal and adequate of the putative class. A direct plaintiff acts on behalf of all other class members in directing the Athira Pharma class action lawsuit. The direct plaintiff can choose a law organization of its option to litigate the Athira Pharma class motion lawsuit. An investor’s skill to share in any potential potential recovery of the Athira Pharma class action lawsuit is not dependent upon serving as direct plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the greatest U.S. law agency symbolizing investors in securities class actions. Robbins Geller lawyers have obtained numerous of the major shareholder recoveries in history, which include the most significant securities course motion restoration at any time – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Motion Expert services Best 50 Report rated Robbins Geller 1st for recovering $1.6 billion for buyers previous yr, more than double the sum recovered by any other securities plaintiffs’ agency. Be sure to stop by for extra facts.

Attorney promoting.
Earlier final results do not guarantee future results.
Expert services may well be carried out by attorneys in any of our offices.

View source variation on


Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]